Drug Type Small molecule drug |
Synonyms ERK-IN-1, LTT-462 |
Target |
Action inhibitors |
Mechanism ERK1 inhibitors(Extracellular-signal-regulated kinase1 inhibitors), ERK2 inhibitors(Extracellular-signal-regulated kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
Molecular FormulaC26H27BrF3N5O2 |
InChIKeyYFCIFWOJYYFDQP-PTWZRHHISA-N |
CAS Registry1715025-32-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
BRAF V600 mutant Colorectal Cancer | Phase 1 | United States | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | Australia | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | Belgium | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | Canada | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | Germany | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | Israel | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | Netherlands | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | Singapore | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | Spain | 22 Jul 2020 | |
BRAF V600 mutant Colorectal Cancer | Phase 1 | United Kingdom | 22 Jul 2020 |
Phase 1 | NRAS Mutant Melanoma | KRAS mutant Non-small Cell Lung Cancer | BRAF Mutation Non-small Cell Lung Cancer KRAS Mutation | BRAF Mutation | NRAS Mutation | 216 | rdpabobhok(xnvimeserh) = fwgxpelsoz wvjigdfern (gxwyzncntb ) View more | Negative | 01 Nov 2024 | ||
rdpabobhok(xnvimeserh) = osetjywufi wvjigdfern (gxwyzncntb ) View more |